Cyfuse Biomedical KK (TSE:4892) Beneish M-Score: -0.66 (As of Jun. 27, 2026)


TSE:4892 Cyfuse Biomedical KK TSE:4892
54 GF Score
Price 円520.00
GF Value 円1,962.33
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Cyfuse Biomedical KK Beneish M-Score?

Cyfuse Biomedical KK TSE:4892 +0.39% 54 Beneish M-Score is -0.66 as of Jun. 27, 2026. GuruFocus rates TSE:4892 with a GF Score™ of 54/100 and a GF Value™ of 円1,962.33 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 911 Drug Manufacturers companies, Cyfuse Biomedical KK ranks worse than 93.52% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Warning Sign:

Beneish M-Score -0.66 higher than -1.78, which implies that the company might have manipulated its financial results.

The historical rank and industry rank for Cyfuse Biomedical KK's Beneish M-Score or its related term are showing as below:

TSE:4892' s Beneish M-Score Range Over the Past 10 Years
Min: -1.99   Med: -0.91   Max: 7.09
Current: -0.66

During the past 6 years, the highest Beneish M-Score of Cyfuse Biomedical KK was 7.09. The lowest was -1.99. And the median was -0.91.


Cyfuse Biomedical KK Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Cyfuse Biomedical KK's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cyfuse Biomedical KK Beneish M-Score Chart

Cyfuse Biomedical KK Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial 0.00 -1.99 -1.16 7.09 -0.66

Cyfuse Biomedical KK Quarterly Data
Dec20 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24 Mar25 Jun25 Dec25 Mar26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.09 0.00 0.00 -0.66 0.00

TSE:4892 vs ZTS: Beneish M-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Cyfuse Biomedical KK's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cyfuse Biomedical KK Beneish M-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cyfuse Biomedical KK's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Cyfuse Biomedical KK's Beneish M-Score falls into.


TSE:4892
54GF Score
Cyfuse Biomedical KK TSE:4892
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cyfuse Biomedical KK Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Cyfuse Biomedical KK for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.1677+0.528 * 0.6277+0.404 * 1.2386+0.892 * 4.2427+0.115 * 1.0604
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.2432+4.679 * -0.053692-0.327 * 1.275
=-0.66

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec25) TTM:Last Year (Dec24) TTM:
Total Receivables was 円45.54 Mil.
Revenue was 円231.00 Mil.
Gross Profit was 円113.89 Mil.
Total Current Assets was 円3,934.46 Mil.
Total Assets was 円4,266.03 Mil.
Property, Plant and Equipment(Net PPE) was 円203.31 Mil.
Depreciation, Depletion and Amortization(DDA) was 円35.49 Mil.
Selling, General, & Admin. Expense(SGA) was 円942.07 Mil.
Total Current Liabilities was 円866.06 Mil.
Long-Term Debt & Capital Lease Obligation was 円642.34 Mil.
Net Income was 円-763.84 Mil.
Gross Profit was 円0.00 Mil.
Cash Flow from Operations was 円-534.79 Mil.
Total Receivables was 円63.99 Mil.
Revenue was 円54.45 Mil.
Gross Profit was 円16.85 Mil.
Total Current Assets was 円3,240.11 Mil.
Total Assets was 円3,518.00 Mil.
Property, Plant and Equipment(Net PPE) was 円192.50 Mil.
Depreciation, Depletion and Amortization(DDA) was 円36.02 Mil.
Selling, General, & Admin. Expense(SGA) was 円912.98 Mil.
Total Current Liabilities was 円648.60 Mil.
Long-Term Debt & Capital Lease Obligation was 円327.00 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(45.535 / 230.999) / (63.987 / 54.446)
=0.197122 / 1.175238
=0.1677

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(16.849 / 54.446) / (113.894 / 230.999)
=0.309463 / 0.49305
=0.6277

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (3934.464 + 203.31) / 4266.026) / (1 - (3240.113 + 192.499) / 3518.001)
=0.030064 / 0.024272
=1.2386

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=230.999 / 54.446
=4.2427

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(36.017 / (36.017 + 192.499)) / (35.494 / (35.494 + 203.31))
=0.157613 / 0.148632
=1.0604

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(942.073 / 230.999) / (912.982 / 54.446)
=4.078256 / 16.768578
=0.2432

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((642.336 + 866.063) / 4266.026) / ((327 + 648.595) / 3518.001)
=0.353584 / 0.277315
=1.275

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-763.843 - 0 - -534.793) / 4266.026
=-0.053692

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Cyfuse Biomedical KK has a M-score of -0.66 signals that the company is likely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -0.66 mean?
Cyfuse Biomedical KK (TSE:4892) has a Beneish M-Score of -0.66 as of Jun. 27, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Cyfuse Biomedical KK and its competitors. According to the industry distribution chart, Cyfuse Biomedical KK ranks #852 out of 911 companies in the Drug Manufacturers industry, placing it in the top 93.5%.
Is Cyfuse Biomedical KK's Beneish M-Score too high?
Cyfuse Biomedical KK's current Beneish M-Score is -0.66. Based on the distribution chart, Cyfuse Biomedical KK ranks #852 out of 911 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Cyfuse Biomedical KK has a GF Score™ of 54/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Cyfuse Biomedical KK's Beneish M-Score compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Cyfuse Biomedical KK ranks #852 out of 911 companies for Beneish M-Score. This places Cyfuse Biomedical KK in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Drug Manufacturers company?
A good Beneish M-Score depends on the Drug Manufacturers industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Cyfuse Biomedical KK and its competitors. Cyfuse Biomedical KK's current Beneish M-Score is -0.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cyfuse Biomedical KK stock overvalued right now?
Based on GuruFocus' analysis, Cyfuse Biomedical KK (TSE:4892) is currently considered Possible Value Trap. The stock's GF Value™ is 円1,962.33, compared to a current price of 円520.00 — trading 73.5% below its estimated fair value. The current Beneish M-Score is -0.66. Cyfuse Biomedical KK's overall GF Score™ is 54/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Cyfuse Biomedical KK (TSE:4892), the current Beneish M-Score is -0.66 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cyfuse Biomedical KK (TSE:4892) Overvalued in 2026?

Based on GuruFocus' analysis, Cyfuse Biomedical KK stock appears to be undervalued. The current stock price of 円520.00 is trading 73.5% below its estimated GF Value™ of 円1,962.33. GuruFocus considers Cyfuse Biomedical KK to be Possible Value Trap.

Key valuation signals for TSE:4892:

  • Beneish M-Score: -0.66
  • GF Value™: 円1,962.33 vs. price of 円520.00 (73.5% below fair value)
  • GF Score™: 54/100 with 5 warning signs

No single metric tells the full story. See the TSE:4892 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Cyfuse Biomedical KK Business Description

Address 3-5-27 Mita, 1st Floor, Sumitomo Real Estate Tokyo Mita South Tower, Minato-ku, Tokyo, JPN, 108-6301
Cyfuse Biomedical KK is engaged in the development, manufacturing, and sales of regenerative medicine-related products. The company focuses on delivering three-dimensional tissues and organs created solely from cells as new 3D cell products to medical fields, including regenerative medicine and drug discovery, through the practical application of three-dimensional cell stacking technology. It is engaged in multifaceted development in the following areas: regenerative medicine, drug discovery support, and the device domain, including the development and sales of 3D cell stacking system equipment, such as bio 3D printers equipped with the company's platform technology.
54GF Score

Get the complete analysis for TSE:4892

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円520.00
Price
円1,962.33
GF Value